You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美國再次延長中國防疫醫療產品301關稅豁免期

據界面新聞消息,當地時間11月23日,美國貿易代表辦公室宣佈,爲應對新冠疫情,將把對中國防疫醫療產品的301關稅豁免再次延長90天,至2023年2月28日。此前的豁免期將於11月30日結束。

關稅豁免範圍涉及81種醫療產品,始於2020年12月29日。此前,相關豁免已多次延期。

從二級市場來看,近期A股醫療走勢較強。截至發稿,九安醫療漲停,迪瑞醫療漲7.09%,熱景生物漲8%。本週以來,九安醫療、迪瑞醫療、熱景生物分別累計上漲23.97%、13.55%、22%。

值得關注的是,九安醫療美國子公司近日還簽訂了一個大單。該公司於23日早間公告,當地時間11月22日,公司美國子公司與美國DLA(美國國防部後勤局,代表美國衛生與公衆服務部),就iHealth新冠抗原家用自測OTC試劑盒產品簽署採購合同並生效,向其銷售iHealth試劑盒產品。合同價稅合計金額1.91億美元,約合人民幣13.67億元,已超過公司2021年主營業務收入的50%。合同履行期限爲一年。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account